Interpace Biosciences, Inc.
IDXG
$1.98
-$0.01-0.50%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.22M | 8.76M | 9.23M | 11.52M | 12.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.22M | 8.76M | 9.23M | 11.52M | 12.41M |
| Cost of Revenue | 3.18M | 3.32M | 3.96M | 4.15M | 4.51M |
| Gross Profit | 6.04M | 5.44M | 5.28M | 7.37M | 7.91M |
| SG&A Expenses | 3.63M | 4.14M | 5.57M | 5.36M | 5.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.95M | 7.61M | 9.70M | 9.69M | 10.35M |
| Operating Income | 2.28M | 1.15M | -468.00K | 1.83M | 2.06M |
| Income Before Tax | 1.54M | 1.00M | -533.00K | 1.77M | 1.86M |
| Income Tax Expenses | -21.22M | -11.00K | -- | 18.00K | -8.00K |
| Earnings from Continuing Operations | 22.75M | 1.01M | -533.00K | 1.75M | 1.87M |
| Earnings from Discontinued Operations | -95.00K | -100.00K | -107.00K | -107.00K | 16.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.66M | 911.00K | -640.00K | 1.65M | 1.88M |
| EBIT | 2.28M | 1.15M | -468.00K | 1.83M | 2.06M |
| EBITDA | 2.40M | 1.26M | -367.00K | 1.92M | 2.16M |
| EPS Basic | 5.12 | 0.21 | -0.14 | 0.37 | 0.32 |
| Normalized Basic EPS | 0.32 | 0.14 | -0.08 | 0.25 | 0.26 |
| EPS Diluted | 0.82 | 0.04 | -0.14 | 0.06 | 0.32 |
| Normalized Diluted EPS | 0.05 | 0.02 | -0.08 | 0.04 | 0.02 |
| Average Basic Shares Outstanding | 4.43M | 4.43M | 4.42M | 4.42M | 4.41M |
| Average Diluted Shares Outstanding | 27.71M | 27.70M | 4.42M | 27.70M | 49.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |